BRAF V600E

CI-VAR-00004575Explore in graph →NP_004324.2:p.Val600GluNM_004333.4:c.1799T>AClinVar 13961 CIViC 12 rs113488022

Curated evidence

Evidence by cancer (259 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 251–259 of 259 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Thyroid Gland Papillary Carcinoma4
BRAF V600E	Vemurafenib	Predictive	B	Supports Sensitivity Response	4	accepted	EID9018 Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positiv… (full text at CIViC) PMID 27460442 · Brose et al., 2016 · Open in CIViC	civic
BRAF V600E	Vemurafenib	Predictive	C	Supports Sensitivity Response	4	accepted	EID1414 A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the … (full text at CIViC) PMID 24987354 · Ali et al., 2014 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Solid Tumors, Advanced1unmapped disease
BRAF V600E	Claturafenib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12640 In the first in human open label phase 1 trial of PF-07799933 for BRAF-mutant advanced solid tumors (NCT05355701; n = 30; BRAFV600E n = 22, BRAF class II/III n = 8), 20 patients with BRAFV600-mutant c… (full text at CIViC) PMID 38691346 · Yaeger et al., 2024 · Open in CIViC	civic

Unmapped disease4unmapped disease
BRAF V600E	(functional)	Functional	B	Supports Gain Of Function	4	submitted	EID13052 In this study, immunofluorescence analysis of treatment-naive melanoma biopsies from 6 patients with BRAF-mutant tumors and 7 patients with BRAF wild-type tumors demonstrated significantly more cortac… (full text at CIViC) PMID 27210749 · Lu et al., 2016 · Open in CIViC	civic
BRAF V600E	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID13067 Exosomes derived from BRAF p.V600E colorectal cancer cells promoted endothelial cell proliferation, migration, and tube formation, increased angiogenic factor expression, enhanced M2 macrophage polari… (full text at CIViC) PMID 35070047 · Zhi et al., 2021 · Open in CIViC	civic
BRAF V600E	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID13068 BRAF p.Val600Glu (V600E) increased glutamate-cysteine ligase (GCLC) expression and intracellular glutathione levels in colorectal cancer patient-derived organoids. CRISPR-mediated GCLC deletion reduce… (full text at CIViC) PMID 36450250 · Laoukili et al., 2022 · Open in CIViC	civic
BRAF V600E	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID13070 Expression of BRAF p.V600E in HCT116 colorectal cancer cells increased cell proliferation, colony formation, migration, and invasion compared with wild-type BRAF or vector controls and was associated … (full text at CIViC) PMID 37168352 · Ma et al., 2023 · Open in CIViC	civic